Dataset Information


RNA sequencing of human, IDH2-mutated, acute myeloid leukemia samples from patients before or during treatment with Enasidenib

ABSTRACT: Mutations in isocitrate dehydrogenase 2 (IDH2) occur in many cancers including Acute Myeloid Leukemia (AML). Recently, we showed that single agent Enasidenib, a first-in-class, selective mutant IDH2 inhibitor, produces a 40% response in relapsed/refractory AML patients by promoting differentiation of leukaemic cells. In this current study, we describe two patients who responded to Enasidenib treatment but subsequently relapsed with an IDH2-mutant subclone which had acquired mutations in DHX15 and DDX1 genes. These genes have putative functions in regulating splicing. We have studied the alternative splicing events using RNASeq in the sample pre-relapse (before acquisition of DHX15 and DDX1 mutations) and at relapse (after acquisition of DHX15 and DDX1 mutations).

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Homo sapiens  

DISEASE(S): Acute Myeloid Leukemia

SUBMITTER: Vijaya Baskar   Lynn Quek  

PROVIDER: E-MTAB-6660 | ArrayExpress | 2018-08-08



Dataset's files

Action DRS
E-MTAB-6660.idf.txt Idf
E-MTAB-6660.idf.txt_original Idf
E-MTAB-6660.sdrf.txt Txt
Items per page:
1 - 3 of 3

Similar Datasets

2018-01-01 | S-EPMC6925974 | BioStudies
2019-01-01 | S-EPMC6384189 | BioStudies
2011-01-01 | S-EPMC3883450 | BioStudies
2018-08-13 | E-MTAB-6299 | ArrayExpress
2018-01-01 | S-EPMC6041864 | BioStudies
2017-01-01 | S-EPMC5572791 | BioStudies
1000-01-01 | S-EPMC5465954 | BioStudies
2014-01-01 | S-EPMC4380188 | BioStudies
2012-01-01 | S-EPMC3293643 | BioStudies
2012-01-01 | S-EPMC3320529 | BioStudies